NEW YORK, July 23, 2014 /PRNewswire/ -- PositiveID
Corp. (OTCQB: PSID), based in Delray
Beach, Fla., is an emerging player in the bio-threat
detection market, that develops molecular diagnostic systems for
bio-threat detection and rapid medical testing. The Company's
proprietary airborne pathogen detection system called M-BAND
(Microfluidic Bio-agent Autonomous Networked Detector), was
developed under contract with the U.S. Department of Homeland
Security ("DHS") Science & Technology directorate, and
$30 million of contract funding.
The Company is nearing initial revenue recognition and the
recent first ever issuance of revenue guidance by management builds
confidence that progress is being made and that we have visibility
to deployment of the Company's products. The Company issued revenue
guidance through the end of 2015 of $4-10
million (combined between 2014 and 2015), $3.5 million of which is already in
backlog.
An analyst report by Small Cap IR detailing the current
situation, summary and investment thesis, an overview of the
company background, product review, current customers, recent
developments, risk factors and analyst recommendation can be viewed
in its entirety by using the link below. There is no cost required
to view this report:
http://bit.ly/-PSID-AnalystResearchReport
copy and paste to browser may be required.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is written and authored by
Michael Anderegg, Chartered
Financial Analyst. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst
report.
If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at editor@smallcaptraders.com. For any urgent concerns or inquiries
please contact us at editor@smallcaptraders.com.
Contact: editor@smallcaptraders.com
SOURCE SmallCapTraders.com